For example, although most of the researches on tumor‐induced immunosuppression have focused on the use of ICB (PD‐1, PD‐L1 and CTLA‐4, etc.)inhibitors, the therapeutic efficacy of them still remains at ≈5–30% range.[46] The low therapeutic efficacy of ICB is related to various antitumor treatment‐induced immunosuppressions in both tumor microenvironment (TME) and tumor‐draining lymph node (TDLN). The gene discussed is CTLA4; the disease is neoplasm.